stockrow
Friday 6 November 2026
Export CSBR’s income statement to Excel — free account
Champions Oncology, Inc.
CSBR Healthcare Biotechnology
Champions Oncology, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $59.4 million, up 4.36% from fiscal 2025.
- Revenue
- +8.84%
- EPS
- 0.00%
- Free cash flow
- −198.7%
Quarter to July 2026, against a year earlier
4.80
0.04
+0.84%
Follow CSBR
Alert me
Champions Oncology, Inc. (CSBR) P/E ratio
Champions Oncology, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 1,096× (September 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 20.4× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 191× | (53.96%) |
| FY2021 | 414× | — |
| FY2020 | 0.0× | — |
| FY2019 | 908× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jul 2026 | 0.0× | — |
| Apr 2026 | 0.0× | — |
| Jan 2026 | 0.0× | — |
| Oct 2025 | 36.0× | 25.32% |
| 43 more quarters | Free account |
Against its own ten years
Low 0.0×
High 1,096×
Ten-year median
0.0×
Current reading's percentile
75
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MNOV MediciNova, Inc. compare | n/m |
| CNXU Conexeu Sciences Inc. compare | n/m |
| NTRB Nutriband Inc. compare | n/m |
| NORD Nordicus Partners Corporation compare | n/m |
| CING Cingulate Inc. compare | n/m |
| ACRV Acrivon Therapeutics, Inc. compare | n/m |
| CSBR Champions Oncology, Inc. | n/m |
| COYA Coya Therapeutics, Inc. compare | n/m |
| MAIA MAIA Biotechnology, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)